| Overview |
| bsm-33859M-FITC |
| IKB beta, FITC Conjugated |
| WB |
| Mouse |
| Human, Rat |
| Specifications |
| FITC |
| Mouse |
| Recombinant human IKB beta |
| Monoclonal |
| IgG |
| 1mg/ml |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4793 |
| Q15653 |
| Cytoplasm, Nucleus |
| I kappa B beta; I-kappa-B-beta; IkappaBbeta; IKB beta; IkB-B; IkB-beta; IKBB; IKBB_HUMAN; IkBbeta; NF kappa BIB; NF-kappa-B inhibitor beta; NF-kappa-BIB; Nfkbib; Thyroid receptor interacting protein 9; Thyroid receptor-interacting protein 9; TR interacting protein 9; TR-interacting protein 9; TRIP-9; TRIP9. |
| Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further NFKBIA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz